The Farletuzumab Biosimilar FOLR1 Antibody is a cutting-edge research tool designed for the study of FOLR1, a cell surface receptor overexpressed in various cancers, including ovarian and breast cancer. This monoclonal antibody, developed for accuracy and specificity, is ideal for research applications such as immunohistochemistry, flow cytometry, and ELISA.FOLR1, also known as folate receptor alpha, is a promising target for cancer therapy due to its high expression in tumor cells and limited expression in normal tissues. Research on FOLR1 has shown potential in the development of targeted therapies for cancer treatment, making this antibody a valuable tool for investigating the role of FOLR1 in cancer biology and assessing its potential as a therapeutic target.
The Farletuzumab Biosimilar Anti-FOLR1 Antibody offers researchers a reliable tool for the detection and analysis of FOLR1 in various cell types and tissues, providing valuable insights into its function and potential as a target for cancer therapy. Its high specificity and sensitivity make it a valuable resource for studies in cancer research and the development of novel treatments for FOLR1-positive cancers.
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Storage & Shipping:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Common Name:
M3,MORAb-003
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
